Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of MAT2A inhibitor for treating asthma

A technology for inhibitors and asthma, applied in the field of medicine, can solve problems that have not been reported yet, and achieve the effect of reducing side effects

Active Publication Date: 2022-02-11
TSINGHUA UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] At present, there is no report on the use of MAT2A as a target in the treatment of asthma.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of MAT2A inhibitor for treating asthma
  • New application of MAT2A inhibitor for treating asthma
  • New application of MAT2A inhibitor for treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] All experimental mice were of C57BL / 6 background and matched for sex and age. All experimental mice were raised in SPF-grade rooms in the Experimental Animal Center of Tsinghua University, with a temperature of 22-26°C and a circadian rhythm of 12 / 12 hours. All operations were strictly complied with the national and Tsinghua University laboratory animal welfare rules and regulations, and the relevant regulations formulated by Tsinghua University Laboratory Animal Use and Management Committee (IACUC).

[0034] To establish an acute asthma model, mice were anesthetized with isoflurane gas, and then 20 μg of papain (both dissolved in 40 μl of 1×PBS) was given by nasal instillation. Mice were intranasally treated with papain on days 0, 1, and 3, and analyzed on day 4. For PF9366 administration, 40 mM PF9366 stock solution was first prepared with DMSO, then diluted with 1×PBS, and 15 μg PF9366 (volume 40 μl) was administered to mice by nasal drops on days -1 to 3.

[0035]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a new application of an MAT2A inhibitor for treating asthma. Specifically, the invention provides an application of the MAT2A inhibitor in the preparation of drugs for treating asthma or related diseases thereof. The invention also provides an application of the MAT2A inhibitor in preparation of a preparation for inhibiting the biosynthesis of a general methyl donor S-adenosylmethionine so as to inhibit the function of type 2 native lymphoid cells. The invention further provides an application of the MAT2A inhibitor in the preparation of a preparation for inhibiting the function of the type 2 native lymphoid cells. Preferably, the function of inhibiting the type 2 native lymphoid cell comprises inhibition or reduction of expression of a type 2 cytokine of the type 2 native lymphoid cell. The invention also provides application of methionine circulation as a target spot in screening and / or preparing medicines for treating asthma or related diseases thereof.

Description

technical field [0001] The invention relates to a new application of MAT2A inhibitors, specifically, the invention relates to a new application of MAT2A inhibitors for treating asthma, and belongs to the field of medical technology. Background technique [0002] Asthma is one of the most common respiratory diseases. It is estimated that 300 million people worldwide suffer from asthma, and the number of cases is still increasing. Patients with asthma generally present with shortness of breath, chest tightness, and cough, accompanied by bronchial hyperresponsiveness and airway inflammation. The pathogenesis of asthma involves a combination of environmental and genetic factors, and a variety of cells including innate and acquired immune cells and epithelial cells are involved, so it is also considered a heterogeneous disease. Generally, antigen-specific type 2 helper T cells (T helper 2, Th2) and their associated type 2 cytokines (mainly IL-4, IL-5 and IL-13) are considered to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/06A61K31/4196A61K9/00A61P11/06A61P11/02A61P37/08A61P29/00
CPCA61K45/06A61K31/4196A61K9/0043A61P11/06A61P11/02A61P37/08A61P29/00
Inventor 郭晓欢付榴辉
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com